Skip to main content
. Author manuscript; available in PMC: 2011 Sep 29.
Published in final edited form as: Gene Ther. 2007 Jun 21;14(16):1189–1198. doi: 10.1038/sj.gt.3302974

Figure 2.

Figure 2

Characterization of antitumor effects generated by treatment with human mesothelin (Hmeso)-expressing DNA vaccine. C57BL/6 mice (five per group) were challenged with 5 × 105/mouse of Defb29 Vegf-luc/Hmeso cells (day 0). Three days after tumor challenge, mice with established Defb29 Vegf-luc/Hmeso tumors were treated with DNA vaccine encoding Hmeso (pcDNA3-Hmeso) via gene gun. An empty vector vaccine (pcDNA3) was used as a control. Mice were imaged using the IVIS Imaging System Series 200. Bioluminescence signals were acquired for 1 min. (a) Luminescence images of representative Defb29 Vegf-luc/Hmeso-challenged mice treated with pcDNA3-Hmeso or pcDNA3 DNA vaccines from day 3 and 60 after tumor challenge. (b) Bar graph depicting the luminescence activity (tumor load) of tumor-bearing mice treated with pcDNA3-Hmeso DNA or pcDNA3 DNA from day 3 and 60 after tumor challenge. (c) Kaplan–Meier survival analysis of the tumor-challenged mice treated with pcDNA3-Hmeso or pcDNA3 DNA vaccines. The mice were tumor challenged on day 0.